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Abstract
Genome-wide association studies have become increasingly common due to advances in tech-
nology and have permitted the identification of differences in single nucleotide polymorphism
(SNP) alleles that are associated with diseases. However, while typical GWAS analysis tech-
niques treat markers individually, complex diseases (cancers, diabetes, and Alzheimers, amongst
others) are unlikely to have a single causative gene. There is thus a pressing need for multi-SNP
analysis methods that can reveal system-level differences in cases and controls.
Here, we present a novel multi-SNP GWAS analysis method called Pathways of Distinction
Analysis (PoDA). The method uses GWAS data and known pathway-gene and gene-SNP asso-
ciations to identify pathways that permit, ideally, the distinction of cases from controls. The
technique is based upon the hypothesis that if a pathway is related to disease risk, cases will
appear more similar to other cases than to controls (or vice versa) for the SNPs associated with
that pathway. By systematically applying the method to all pathways of potential interest, we
can identify those for which the hypothesis holds true, i.e., pathways containing SNPs for which
the samples exhibit greater within-class similarity than across classes. Importantly, PoDA im-
proves on existing single-SNP and SNP-set enrichment analyses in that it does not require the
SNPs in a pathway to exhibit independent main effects. This permits PoDA to reveal pathways
in which epistatic interactions drive risk.
In this paper, we detail the PoDA method and apply it to two GWA studies: one of breast
cancer, and the other of liver cancer. The results obtained strongly suggest that there exist
pathway-wide genomic differences that contribute to disease susceptibility. PoDA thus provides
an analytical tool that is complementary to existing techniques and has the power to enrich our
understanding of disease genomics at the systems-level.
Author Summary
We present a novel method for multi-SNP analysis of genome-wide association studies. The method
is motivated by the intuition that if a set of SNPs is associated with disease, cases and controls
will exhibit more within-group similarity than across-group similarity for the SNPs in the set of
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interest. Our method, Pathways of Distinction Analysis (PoDA), uses GWAS data and known
pathway-gene and gene-SNP associations to identify pathways that permit the distinction of cases
from controls. By systematically applying the method to all pathways of potential interest, we
can identify pathways containing SNPs for which the cases and controls are distinguished and infer
those pathway’s role in disease. We detail the PoDA method and describe its results in breast and
liver cancer GWAS data, demonstrating its utility as a method for systems-level analysis of GWAS
data.
Introduction
Genome-wide association studies (GWAS) have become a powerful and increasingly affordable
tool to study the genetic variants associated with disease. Modern GWAS yield information on
millions of single nucleotide polymorphism (SNPs) loci distributed across the human genome, and
have already yielded insights into the genetic basis of complex diseases [1, 2], including diabetes,
inflammatory bowel disease, and several cancers [3, 4, 5, 6, 7]; a complete list of published GWAS
can be found at the National Cancer Institute–National Human Genome Research Institute (NCI-
NHGRI) catalog of published genome-wide association studies [8].
Typically, the data produced in GWAS are analyzed by considering each SNP independently,
testing the alleles at each locus for association with case status; significant association is indicative
of a nearby genetic variation which may play a role in disease susceptibility. Genomic regions of
interest may also be subject to haplotype analysis, in which a handful of alleles transmitted together
on the same chromosome are tested for association with disease; in this case, the loci which are
jointly considered are located within a small genomic region, often confined to the neighborhood
of a single gene.
Recently, however, there has been increasing interest in multilocus, systems-based analyses.
This interest is motivated by a variety of factors. First, few loci identified in GWAS have large effect
sizes (the problem of “missing heritability”) and it is likely that the common–disease, common–
variant hypothesis [9, 10] does not hold in the case of complex diseases. Second, single marker
associations identified in GWAS often fail to replicate. This phenomenon has been attributed to
underlying epistasis [11], and a similar problem in gene expression profiling has been mitigated
through the use of gene-set statistics. Most importantly, it is now well understood that because
biological systems are driven by complex biomolecular interactions, multi-gene effects will play
an important role in mapping genotypes to phenotypes; recent reviews by Moore and coworkers
describe this issue well [10, 12]. Additionally, the finding that epistasis and pleiotropy appear to
be inherent properties of biomolecular networks [13] rather than isolated occurences motivates the
need for systems-level understanding of human genetics.
The impact that biological interaction networks have on our ability to identify genomic causes
of complex disease is readily apparent. Consider a biologically crucial mechanism with several
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potential points of failure, such that an alteration to any will confer disease risk. Because no
single alteration is predominant amongst cases, none attain a significant association; indeed, it
has long been observed that even in histologically identical tumors, only a fraction may share
the same set of mutations (see references in [14] for examples). Additionally, in a robust system,
multiple alterations may be necessary to alter the activity of an interaction network; here, healthy
individuals may share a subset of the deleterious alleles found in cases, and again these loci will
not be detected. This complexity, noted by [10, 12, 13, 14] and others, has generated considerable
interest in multi-locus analysis techniques that take advantage of known interaction information.
Several multi-SNP GWAS analysis approaches have been described in the literature. Thorough
reviews are provided in [15, 16], and we briefly describe several here. Building on the well-established
Gene Set Enrichment Analysis [17] method initially developed for gene expression data, two articles
have proposed an extension of GSEA for SNP data [18, 19]. In these techniques, each SNP is
assigned a statistic based on a χ2 test of association with the phenotype; a running sum is then
used to assess whether large statistics occur more frequently amongst a SNP set of interest than
could be expected by chance. While GSEA-type approaches have proven quite useful, their reliance
on single-marker statistics means that systematic yet subtle changes in a gene set will be missed
if the individual genes do not have a strong marginal association. In the case of a purely epistatic
interaction between two SNPs in a set, the set may fail to reach significance altogether.
To address this issue, Yang and colleagues proposed SNPHarvester [20], designed to detect
multi-SNP associations even when the marginal effects are weak. To reduce the search space of
possible multi-SNP effects, SNPHarvester [20] first removes any SNPs with univarite significance.
Using a novel searching algorithm, they identify groups of l SNPs that show association with status
in a χ2 test with 3l−1 degrees of freedom. While this approach can reveal epistatic effects that would
be missed by the GSEA-type schemes [18, 19], it has other drawbacks. First, the combinatorial
explosion of SNP groups puts a limit on the number of SNPs l that may simultaneously be examined.
Second, the the arbitrary groupings of SNPs and the exclusion of SNPs with marginal effects can
make the biological interpretation of the analysis results difficult.
The notion that cases will more closely resemble other cases than they will controls has moti-
vated a number of interesting distance-based approaches for detecting epistasis. Multi-dimensionality
reduction (MDR) has been proposed and applied to SNP data [21, 22, 23]. In this technique, sets
of l SNPs are exhaustively searched for combinations that will best partition the samples by exam-
ining the 3l cells in that space (corresponding to homozygous minor, heterozygous, or homozygous
major alleles for each locus) for overrepresentation of cases. While this method both finds epistatic
interactions without requiring marginal effects and can be structured to incorporate expert knowl-
edge, it is limited by the fact the the total number of loci to be combinatorially explored must
be restricted to limit computational cost. To address this, an “interleaving” approach in which
models are constructed hierarchically has been suggested [22] to reduce the combinatorial search
space. A recent and powerful MDR implementation [24] taking advantange of the CUDA parallel
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computing architecture for graphics processors has made feasible a genome-wide analysis of pair-
wise SNP interactions. Still, MDR remains computationally challenging, such that expanding the
search to other SNP set sizes (rather than restricting to pairwise interactions) can be impeded by
combinatorial complexity if an exhaustive search is to be performed.
In order to narrow down the combinatorial complexity of discovering SNP sets using techniques
such as MDR, feature selection may be employed. Of particular importance here is the distance-
based approach of the Relief family of algorithms [25, 26, 27, 28]. These are designed to identify
features of interest by weighting each feature through a nearest-neighbor approach. The weights are
constructed in the following way: for each attribute, one selects samples at random and asks whether
the nearest neighbor (across all attributes) from the same class and the nearest neighbor from the
other class have the same or different values from the randomly chosen sample. Attributes for which
in-class nearest neighbors tend to have the same value are weighted more strongly. Because the
distances are computed across all attributes, Relief-type algorithms can identify SNPs that form
part of an epistatic group and they provide a means of filtration that does not have the drawbacks
of other significance filters.
While these methods have so far been applied to finding small groups of interacting SNPs,
one may instead be interested in whether cases and controls exhibit differential distance when
considering a large number of genes. A multi-SNP statistic has been proposed in the literature [29,
30, 31] for determining whether an individual of interest is on average (across a large number of
SNPs) “closer” to one population sample than to another. The method, originally proposed by
Homer [29], is motivated by the idea that a subtle but systematic variation across a large number
of SNPs can produce a discernible difference in the closeness of an individual to one population
sample relative to another. While this statistic was originally designed to identify the proband as
a member of one of the population samples, it was shown in [30] that out-of-pool cases from a
case-control breast cancer study were in general closer (as defined by the statistic presented in [29])
to in-pool cases than they were to in-pool controls, suggesting that the combination of multiple
alleles has the potential to distinguish cases from controls.
Building on these ideas, we present a new technique that finds pathway-based SNP-sets that
differentiate cases from controls; we call this method Pathways of Distinction Analysis (PoDA). In
PoDA, SNP sets are defined based on known relationships (e.g., SNPs in genes sharing a common
pathway), and thus incorporate expert knowledge to reduce the search space and provide biological
interpretability. Motivated by the differential “closeness” of cases and controls as discussed about
and as observed in [30], we hypothesize that if the SNPs come from a pathway that plays a role
in disease, there will be greater in-class similarity than across-class similarity in the genotypes for
those SNPs; i.e., a case will show greater genetic similarity to other cases than to controls for the
SNPs on a disease-related pathway, but will be equidistant for the SNPs on a non-disease-related
pathway. Based on this notion, PoDA seeks to identify pathways for which differential heterogeneity
is exhibited in cases and controls. In each pathway, PoDA returns a statistic S for each sample that
4
quantifies that sample’s distance to the remaining cases relative to its distance to the remaining
controls for a given pathway’s SNPs. PoDA then examines whether the distributions of S for
the controls differ from those of the cases by computing and testing for significance a Pathway
Distinction Score DS that quantifies the differences in case and control S distributions. In this
manuscript, we detail the PoDA method and report the results of its application to two data sets.
As we will describe, PoDA improves and complements existing approaches in a number of
respects. First, it permits the investigation of arbitrarily large pathways, circumventing the dimen-
sionality issues that are encountered with MDR and SNP-Harvester. Second, it is able to detect
pathways that contain an over-abundance of highly-significant markers as well as pathways whose
markers have a small but consistent association that would be missed by GSEA-type approaches.
Finally, it uses a leave-one-out technique to return for each sample an unsupervised relative dis-
tance statistic that can then be used to model disease risk via logistic regression. In addition to
providing an effect size for the pathway, this allows the odds of disease for new samples to be ob-
tained by computing its relative distance statistic with respect to the known samples and applying
the model.
Methods
Following our conjecture that SNPs associated with the genes in a pathway involved in disease
will exhibit more within-group similarity than across-group similarity, we propose Pathways of
Distinction Analysis (PoDA), a method designed to address the following questions:
• Given some set of SNPs, do we find that, on average, cases are “closer” to other cases than
to controls (or that controls are “closer” to other controls than to cases)?
• If we look for these distinctions systematically over all SNP-sets of potential interest, can we
use it to single out SNP-sets which may be associated with disease?
In PoDA, a set of SNPs are selected, and for each sample we compute whether it is closer to
the pool of remaining cases or controls across that SNP set, using the relative distance statistic
described below. Once this is done for every sample, the distribution of the relative distance
statistic is compared in the cases and controls using a nonparametric statistic, addressing the first
question above. This may be carried out amongst all SNP sets of interest, adjusting the p-value for
the multiple hypotheses, to find SNP sets for which cases more strongly resemble the population
of remaining cases while controls more strongly resemble the population of remaining controls.
We begin with a discussion of how we measure the relative distance of an individual to the
other cases vs. other controls. A simple but computationally intensive approach is to represent
each sample by a vector in an l-dimensional space, where l is the number of SNPs in the group
of interest. One can then compute, between each sample pair, their distance in this l-dimensional
space using a Euclidean, Manhattan, or Hamming metric. For each sample, we would define its
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relative distance statistic as the mean of its distance to other controls minus the mean of its distance
to other cases; a sample that is more similar to cases will exhibit a positive statistic, whereas one
that is more similar to other controls will exhibit a negative statistic. For the given SNP set,
we would then have for each sample a value quantifying its relative distance that was computed
without knowledge of that sample’s class (i.e., using a leave-one-out scheme) and could then be
used in further tests. By doing this for all pathways of interest, one derives a relative distance value
for each sample in each pathway.
This brute-force approach, while conceptually clear, has two significant drawbacks. The first is
that the distance computation is O(l · n2) where n is the total number of samples in the study—a
considerable undertaking, particularly if many SNP sets are to be analyzed, and one that becomes
exceedingly troublesome in the context of permutation tests. The second drawback is that because
we are taking the mean of the distances, a sample that is situated squarely within a cluster of
cases may have a large case-distance value due to the dispersion of cases around it. Both of these
issues are circumvented by instead considering the relative distance to the centroids of the cases
and controls in the l-dimensional space, a computation that can be performed in O(l · n) for all n
samples. It is this approach that PoDA employs, as follows:
In [30, 29], the authors consider a measure of individual Y ’s distance to two population samples
F and G at locus i,
DY,i = |yi − fi| − |yi − gi| . (1)
where fi and gi are the minor allele frequencies (MAFs) of SNP i in samples F and G, and yi ∈
{0, 0.5, 1} is Y ’s genotype at i corresponding to homozygous major, heterozygous, and homozygous
minor alleles, respectively (i.e., the frequency of minor allele in that individual. The first term
quantifies how different Y ’s MAF is from F ’s for a given locus i; the second term quantifies how
different Y ’s MAF is from G’s at locus i; and so DY,i gives the distance of Y relative to F and G
at locus i. Since the minor allele frequencies fi and gi are computed by averaging the genotypes
(again, written as {0, 0.5, 1}) in samples F and G respectively, it is clear that |yi − fi| is the distance
from Y to the centroid of F along the coordinate i (and likewise for the gi term). It can be seen
from Eq. 1 that positive DY,i implies that yi is closer to gi than to fi, and that negative DY,i implies
that yi is closer to fi than to gi.
By computing DY,i at each locus i and taking the standardized mean across the l loci, [29]
obtain a distance score S which quantifies how close Y is relative to F and G across all l loci under
consideration,
SY =
E(DY,i)√
Var(DY,i)/l
, (2)
where E(DY,i) denotes the mean of DY,i across all loci i. That is, S provides a means to quantify
whether Y ’s MAFs are closer to G’s MAFs or F ’s MAFs on average for the loci under consideration.
It is instructive to consider the geometrical interpretation of Eq. 2. Is clear upon inspection that the
numerator in Eq. 2 is equal, up to a factor of l, to the difference in Manhattan distances between Y
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and the (nonstandardized) G centroid and Y and the (nonstandardized) F centroid; in this sense,
Eq. 2 resembles a nearest-centroid classifier. However, the denominator scales the relative distances
by their variance across the l SNPs; that is, a sample Y who is consistently closer to G than to F
for each of the l SNPs will obtain a higher S than an individual who is variously closer to either
across the l SNPs under consideration.
By assigning the (non-Y ) controls as F and the (non-Y ) cases as G, we can compute a statistic
SY quantifying Y ’s distance to other cases relative to Y ’s distance to other controls. If we then
apply this systematically to all individuals in the study population (removing that individual,
computing the MAF’s fi and gi for the remaining individuals who comprise F and G, and then
computing SY in a leave-one-out manner), we can obtain distributions of SY statistics in cases and
controls that may be compared. Here, the null hypothesis is that case and control SY distributions
do not differ, with the alternative hypothesis that the cases have higher S values than do controls,
i.e., that they are closer (via Eqs. 1-2) to other cases than are controls.
We can use S in the following manner to answer the questions posed above by applying it in a
leave-one-out manner in each pathway:
1. For a given pathway P , select the lP SNPs associated with that pathway;
2. For every sample Y , remove Y from the case or control group as needed, and compute SY,P
with respect to the remaining cases and controls using the SNPs chosen in step 1.
3. Quantify the differences in distribution of SY,P ’s for the case samples versus that of the
controls and test for significance.
By systematically carrying out the above steps on all pathways of interest, we can identify pathways
for which there appears to be differential homogeneity in cases and controls, indicating that the
pathway may play a disease-related role. The details of the algorithm are explained below, and
summarized in Table 1.
In [30], we examined Eqs. 1-2 and found that the magnitude of S is influenced both by the
MAF differences fi − gi (that is, how distant the centroids of F and G are) and by correlations
between the SNPs under consideration (due to the penalization for variance in Di provided by the
denominator of Eq. 2. These properties are extremely well-suited to the application we propose:
pathways with few highly-significant SNPs will yield large S differences (due to the influence of
fi − gi), as will pathways with SNPs that are highly correlated yet have subtle individual MAF
differences, corresponding to the concerted action of multiple SNPs.
At the same time, however, we wish to ensure that the pathways we select as having differential
S are not being influenced large LD blocks covered by the SNPs in the genes on the pathway.
That is, we wish to ensure that the SNP correlations which drive S are reflective of epistatic effects
between different genes rather than recombination events within a gene. To this end, we select a
single SNP to represent each gene, based on the desire to detect multi-gene rather than multi-SNP
effects.
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In practice, SNPs are selected as follows: for each pathway represented in the Pathway In-
teraction Database [32] (PID, http://www.pid.nci.gov, containing annotations from BioCarta,
Reactome, and the NCI/Nature database [32]) and KEGG [33], we select the associated genes.
Using dbSNP [34], we retrieve the SNPs associated with the pathway genes that are present in
the data, excluding those with > 20% missing data or with minor allele frequency < 0.05 in either
case of control group. We necessarily exclude pathways for which only one gene is probed by the
remaining SNPs. Because we are interested in S values that are driven by correlations across genes
(and not in individual genes covered by many SNPs with high LD), we select for each gene its most
significant SNP in a univariate test of association (Fisher’s exact test). It should be noted here that
while the SNP chosen for each gene is the most significant of that gene’s SNPs, it is not necessarily
significantly associated with disease. Our goal here is not to filter based on SNP significance, but
rather to select, for each gene, a single marker that is as informative as possible.
Having selected the SNPs of interest, we compute DY,i at each locus for every sample by
selectively removing it and comparing it to the remaining cases and controls, as described above.
For each pathway P , we compute SY,P for lP the SNPs i that comprise it, yielding a distribution of
SY,P for cases and another distribution for controls. The difference in the location of the case and
control SY,P distributions is then quantified nonparametrically by computing the Wilcoxon rank
sum statistic, defined as
WP =
∑
Y ∈case
RY,P − ncase(ncase + 1)
2
(3)
where RY,P is the rank of SY,P amongst all samples Y for a given pathway P . Eq. 3 thus quantifies,
non-parametrically, the degree to which cases are “closer” to other cases and controls “closer” to
other controls across a set of SNPs for all individuals in the GWAS.
To illustrate the above, we consider a simulated GWAS of 250 cases and 250 controls and 50
SNPs, shown in Figure 1, and ask whether we are able to detect a 12-SNP pathway in which a
subset of SNPs appear to have an epistatic interaction. Alleles were simulated as binomial samples
from a source population with MAFs ranging from 0.1 to 0.4 across the 50 SNPs, and case labels
were assigned such that a combintion of homozygous minor alleles at SNPs 1 and 2 or 3 (i.e.,
(y1 = 1) ∧ ((y2 = 1) ∨ (y2 = 1))) conferred a three-fold relative risk, mimicking an epistatic
interaction between SNPs 1 and 2 and SNPs 1 and 3 (Figure 1(a)). Alone, none of the 50 SNPs
showed any association with case status, nor was any SNP significantly out of HWE in either cases
or controls. However, the “shared pattern” in SNPs 1–3 is such that a 12 SNP pathway comprising
SNPs 1–12 yields greater S in cases than in controls as can been seen in Figure 1(b), while a random
12 SNP pathway selected from the 50 SNPs (that includes SNP 3, but neither SNP 1 or 2) shows
no difference in S values as seen in Figure 1(c).
While the Wilcoxon statistic W is normal in the large-sample limit and can be directly compared
to a Gaussian, to truly evaluate the significance of WP for a given pathway P , we must address two
sources of bias: the number of SNPs per gene, and the size of the pathway. To address these issues,
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we introduce a normalized Pathway Distinction Score DSP that we test for significance using a
resampling procedure.
First, we expect that because we have selected for each gene the single most informative SNP,
we are pre-disposed to seeing higher WP for pathways that contain large genes. Because large
genes will be more likely to contain highly-significant SNPs by chance, the concern has been raised
that [35, 18] selecting the single most significant SNP as a proxy for the gene (as is done here)
will lead to a bias toward pathways that contain an abundance of large genes. To account for this,
we follow the approach in [18] and normalize the score via a permutation-based procedure. First,
we permute the phenotype labels and in each permutation recalculate WP as described above, but
using the permuted case and control labels. The permuted labels are used both to select the most
informative SNP per gene and to compute fi, gi, and WP in Eqns. 1–3). This yields a distribution
of W ∗P under the null hypothesis that the magnitude of W is independent of the true case/control
classifications. We then normalize the true WP by the distribution from the permutation procedure,
yielding a Distinction Score DSP for pathway P that effectively adjusts for different sizes of genes
and preserves correlations of SNPs in the same gene:
DSP =
WP − E(W ∗P )
SD(W ∗P )
, (4)
where W ∗P are the set of WP obtained for pathway P across the permutations. (In practice,
100 permutations are used.) Because the permuted labels are used in the SNP selection, this
normalization adjusts for the bias introduced by the fact that large genes have more opportunity to
contain significant SNPs by chance. The Pathway Distinction Score DSP thus provides a model-
free, gene-size adjusted metric for quantifying the degree to which cases are “closer” to other cases
(higher SP ) than controls.
To test whether DSP is significant, we note that larger pathways may yield high DSP values
simply due to the fact that they sample the case anc control differences more thoroughly. Indeed,
the question of significance that we wish to address is not simply whether a pathway permits the
distinction of cases and controls, but whether it does so better than a random collection of as many
SNPs, wherein the SNPs are still selected to be the most informative by gene. To account for
the fact that the pathways are of differing sizes, significance of the Distinction Score for a given
pathway is assessed through resampling by choosing, at random, the same number of SNPs that are
present in that pathway (lP ) from the total set of most-informative-SNP-per-gene and recomputing
DSP for the random pathway. The p value is obtained by counting the fraction of random lP -SNP
sets which give a larger DSP than the true pathway SNPs in 10
4 resamplings. In this way, we are
able to detect pathways that yield large differences of case and control S distributions due to their
particular SNPs, rather than simply being the result of choosing many SNPs. The p value obtained
addresses the question of whether the pathway under consideration permits greater separation of
cases and controls than would a random collection of most-informative-SNP-per-gene, i.e., whether
there exists a more extreme aggregated effect in that pathway than expected by chance.
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Results
We applied PoDA to 2287 genotypes obtained from the Cancer Genomic Markers of Susceptibility
(CGEMS) breast cancer study. The samples were sourced as described in [4]. Briefly, the samples
comprised 1145 breast cancer cases and a comparable number (1142) of matched controls from the
participants of the Nurses Health Study. All the participants were American women of European
descent. The samples were genotyped against the Illumina 550K arrays, which assays over 550,000
SNPs across the genome.
We also applied it to a smaller liver cancer GWAS [36] comprising 386 hepatocellular carcinoma
(HCC) patients and 587 healthy controls from a Korean population. Samples were genotyped
against Affymetrix SNP6.0 arrays, which provides SNP information at approximately one million
loci.
Breast cancer GWAS results
We begin by applying PoDA to the CGEMS breast cancer GWAS data. Having observed (Figure 1)
that PoDA performs as expected for the simulated data, we first turn our attention to a simple test
in which we select a SNP set comprising the four SNPs in intron 2 of FGFR2 that were reported to
show significant association with case status in [4] (rs11200014, rs2981579, rs1219648, rs2420946).
We expect to see a strong difference in the test case and test control distributions, and indeed we
do: the cases more frequently have positive S than do controls in Fig. 2. (The discrete peaks in
the distribution are a result of the fact that with four SNPs there exist fewer available values of
S.) Using a nonparametric Wilcoxon rank sum test with the alternative hypothesis that cases have
greater S than controls, p = 1.016 · 10−6 is obtained, confirming our intuition.
We next applied PoDA systematically to the pathways represented in PID [32] using CGEMS
data. Associations between genes and SNPs were made using dbSNP build 129 [34]. 1081 pathways
were non-trivially covered in the data set; 69453 SNPs in the data could be associated with at least
one of the pathways. Because these 69453 SNPs were associated with 4446 unique genes, 4446
were kept in the analysis (the most significant SNP for each gene of interest). The 1081 pathways
ranged from 2 to 229 genes, with a mean of 19. SY,P was computed in each pathway P for each
of the 2287 samples Y via Eq. 2, and the distinction score DSP (Eq. 4) quantifying differential S
distributions in cases and controls was computed for each pathway. Significance was assessed as
described above, by resampling “dummy” pathways of the same length and computing the fraction
of greater DSP scores.
Because PoDA provides for each sample a measure S (Eq. 2 of that sample’s relative distance
from the remaining ones that is obtained without regard to that sample’s true class membership,
we can use the S value as a metric by which to predict the odds of disease. Here, we construct a
logistic regression model of case status as a function of S to obtain the odds ratio. p-values were
adjusted for the multiplicity of pathways using FDR adjustment [37, 38].
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Pathways with significant DSP and odds ratios are reported in Table 2 and plots of S for four of
them are illustrated in Figure 3. Although the cases and controls are not crisply separable, a unit
increase in S over its range from approximately -3 to 3 yields between a 1.5 and 2.0-fold increase
in odds. Importantly, given known minor allele frequencies for cases and controls for this set of
SNPs, we can model the increase in odds for an unknown individual based on her “closeness” to
other cases.
In order to ensure that the pathways listed were not interrogating the same set of genes, we car-
ried out two checks. First, we computed the SNP overlap between all pairs of significant pathways,
sequentially removing pathways that shared in excess of 60% of their genes with another pathway.
Because this is done using a greedy algorithm that depends on the order of the pathways input, the
culling algorithm was run with different starting orders, and the most frequent output was kept.
No pathway remaining in Table 2 shares more than 60% of its SNPs with another pathway. (An
un-culled list may be found in Supplementary Table S-1.) Second, we computed the correlation of
S values between each pair of pathways to assess whether any pathway’s S statistic was reflecting
the same genetic variation as another (i.e., whether samples that had high S values for one path-
way consistently did so in another). The maximum correlation of S values observed between any
two pathways in Table 2 was 0.58, suggesting that a different subset of samples is affected in each
pathway.
Many of the pathways listed in Table 2 fulfill biological functions that are well known to be
cancer-associated, playing a strong role in cell proliferation and migration, processes which are
perturbed in malignancies. Purine metabolism—the most significantly associated pathway—has
been observed to be altered in cancer cells [39, 40], and the majority of the other significant
pathways are directly related to cell migration (e.g., ErbB signaling and gap junction pathways) and
cellular signalling (e.g., calcium signaling, PKC-catalyzed phosphorylation of myosin phosphatase,
attenuation of GPCR signaling, and activation of PKC through GPCRs) processes that have been
implicated in a variety of cancers. In addition, eicosanoids and unsaturated fatty acid metabolism
have been associated with breast cancer specifically [41]. In general, the findings in Table 2 suggest
that there exist germline genetic differences in these mechanisms that confer a predisposition to
disease.
Interestingly, the GnRH (gonadotropin releasing hormone) signaling pathway appears to be
significant. GnRH has been linked with HR-positive breast cancer and the use of GnRH analogues
in breast cancer treatment has already been proposed [42, 43]. However, a recent large sequencing
study found no association of GnRH1 or GnRH receptor gene polymorphisms with breast cancer
risk [44], contrary to the author’s hypothesis that common, functional polymorphisms of GnRH1
and GnRHR could influence breast cancer risk by modifying hormone production. In contrast to
their null findings, our result suggests that there are system-wide variations in GnRH signalling
that contribute to risk that are not evident when considering the GnRH1 and GnRHR SNPs
independently.
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Of the 1081 pathways considered, four—FGF signaling, MAPK signaling, regulation of actin
cytoskeleton, and prostate cancer—contained FGFR2 , the gene found to be significantly associated
in the initial CGEMS analysis [4]. However, only one—prostate cancer—was significant in compari-
son to randomly generated pathways of the same length. It may reasonably be asked, then, whether
the high significance of the prostate cancer pathway in Table 2 is a result of FGFR2 . To address
this, we eliminated the FGFR2 SNP from the prostate cancer pathway; the resampling-based test
remained significant (p(DSP ) = 0.044, OR = 0.3, q(OR) = 8.2e-09), suggesting that the association
of the prostate cancer pathway is not driven solely by differences in FGFR2 .
Liver cancer GWAS results
We carried out the same procedure in using data from the liver cancer GWAS described above.
Here, 1049 pathways were non-trivially covered in the data set; 53079 SNPs in the data could be
associated with at least one of the pathways. Because these 53079 SNPs were associated with 3718
unique genes, 3718 were kept in the analysis (the most significant SNP for each gene of interest). The
1081 pathways ranged from 2 to 193 genes, with a mean of 16. As above, DSP scores for differential
S distributions in cases and controls were computed for each pathway, resampled p values obtained
for each pathway size, odds ratios for S were obtained, and the multiple hypotheses were corrected
using FDR adjustment [37, 38]. Significant pathways are listed in Table 3, and plots of the top three
pathways are given in Figures 4a-d. As in the breast cancer data above, we removed pathways which
had over 60% their SNPs covered by another pathway (a complete list, with overlapping pathways,
is give in Supplementary Table S-2) and examined the correlation in S for all remaining pathways
(maximum ρ = 0.42).
The results here are interesting. First, we observe that a couple pathways are significant in
both the CGEMS breast and liver GWAS with similar effect sizes, namely ErbB signaling and
biosynthesis of unsaturated fatty acids. ErbB has a well–established association with cancer; un-
saturated fatty acid biosynthesis may link diet to cancer risk, and its appearance may suggest a
gene-environment interaction. The commonality of these known cancer-associated pathways across
the two studies suggest that there may exist genetic patterns that confer carcinogenesis risk ir-
respective of the disease site. Along with those shared in the breast cancer data, many of the
other significant pathways in the liver cancer data well known to be tumorassociated, including cell
adhesion molecules, Wnt signaling, c-Kit receptor, and angiogenesis pathways, further supporting
the notion that germline genetic differences in these mechanisms contribute to cancer risk. The
appearance of many neuronal pathways is also supported by our understanding of carcinogenesis:
thes contain well-known signal transduction molecules including Ras and PKA that may both be
driving their conferring increased cancer risk and driving the significance of the pathway [45].
Additionally, six of the 25 significant liver cancer pathways are immune– and inflammation–
related, namely, antigen processing and presentation (two, with <60% overlap), classical com-
plement pathway, corticosteroids, IL12 signaling mediated by STAT4, and NO2-dependent IL-12
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pathway in NK cells. This is a particularly interesting finding in light of the fact that the orig-
inal analysis of the liver data [36] suggested that altered T-cell activation plays a direct role in
the onset of liver cancer. The involvement of the immune system in liver cancer development has
been established in clinical studies and research involving model organisms. Increased activity of
helper T-cells, which promote inflammation, is associated with hepatocellular carcinogenesis [46]
while activation and proliferation of cytotoxic T-lymphocytes is suppressed in liver cancers [47, 48].
The inflammatory immune response, mediated by interleukins, has also been closely connected to
liver cancers in mice [49] and humans [50, 51, 52]. These findings, coupled with the observation of
several significant immune-related pathways in our data, are suggestive of germline polymorphisms
in immune response that lead to hepatocellular carcinoma risk.
Combining pathways
In both the breast and liver cancer results, we see observe that even though significant pathways
yield between a 1.5 and 2.0-fold increase in odds for each unit increase in S (over its typical range of
approximately −3 to 3), the cases and controls are not crisply separable based on S values. These
findings suggest that it may be possible to combine pathways to yield a model that is more predictive
than a single pathway alone. However, the S values must not simply be put into the regression
model because the overlap in pathways will result in some SNPs being double-counted. Rather, we
combine pathways by taking the union of their SNPs, and recomputing the statistics. Doing this
sequentially for the top pathways in the order as listed in Tables 2 and 3 yields the values given in
Tables 4 and 5, respectively. Considerably higher ORs are obtained when combining the significant
pathways. An illustration of the case and control distributions when using a “superpathway”
comprised of the top three pathways in the breast and liver data, respectively, is given in Figure 5.
These findings support the notion that the genomic variation contributing to risk is spread over
several mechanisms, rather than being concentrated in a single gene.
Discussion
We have introduced the Pathways of Distinction analysis method (PoDA) for identifying pathways
which can be used to distinguish between phenotype groups. PoDA identifies sets of SNPs in GWAS
studies for which cases and controls exhibit differential “closeness” to other cases and controls; that
is, it permits one to infer whether cases are more similar to other cases than are controls across
a given set of SNPs. Because PoDA is designed to detect the joint effects of multiple SNPs, it
presents an approach to GWAS analysis that augments single-SNP or single-gene tests.
We applied PoDA to two GWAS data sets, with highly promising results. In the breast cancer
data, we found a number of pathways which are known to play a role in cancers generally and
breast cancer specifically, suggesting that differences in these mechanisms which confer disease risk
may exist at the germline DNA level. In the liver cancer data, we found an extreme abundance of
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immune-related pathways, further corroborating the known link between inflammation and hepa-
tocellular carcinoma, and bolstering the observation in [36] that germ-line differences in immune
function may play a role in liver carcinogenesis.
PoDA may be used as a complement to other multi-SNP analysis techniques [18, 19, 20, 21].
Unlike gene-set enrichment type approaches [17, 18, 19], which search for an overabundance of
significant markers in a gene set of interest, PoDA finds both sets containing highly significant
markers as well as sets that have a subtle but consistent pattern across all the markers in the set.
This permits the detection of pathways in which the joint action of several alterations produce a
phenotype and those for which any of several possible alterations, none of them the dominant one,
confer predisposition to disease. Indeed, many of the pathways indicated in our analysis of the
breast cancer data (Table 2) were not detected using SNP-set enrichment [17, 18, 19] (data not
shown), including the highly significant purine metabolism and GnRH signaling pathways, both
of which are biologically relevant (purine metabolism has been implicated in cancers generally due
to its role in DNA and RNA synthesis [40], and GnRH has been shown to be clinically important
in breast and gynecological cancers [53]). These pathways, along with others that were indicated
using PoDA but not enrichment analysis (data not shown), have a statistically significant difference
in case and control S distributions and remain significant in comparison with randomly-generated
pathways of the same length.
Because PoDA effectively measures the closeness of each individual to remaining cases and
controls, it bears a conceptual relationship to nearest-neighbor and nearest-centroid classifiers [54,
55], as well as to the distance-based feature selection algorithms like Relief-F and its derivatives [25,
26, 27, 28]. However, it must be remembered that the goal of PoDA is to indicate mechanisms that
may be deleteriously hit at the genomic level even when those hits are heterogeneous, whereas the
goal of nearest-centroid classifiers and Relief-F–type feature selection is to derive a minimal set of
markers that best classify cases and controls (and thus are the most homogeneously hit). These
approaches are complementary, and one can easily envision an application in which (e.g.) Relief-F is
run within pathways that are highly significant in the PoDA analysis in order to single out the SNPs
driving the effect. In fact, this approach may improve ReliefF’s ability to find those genes, since the
nearest neighbors from which the Relief SNP weights are calculated would be the nearest-neighbors
for that specific pathway, thus discounting heterogeneity introduced by mechanistically unrelated
genes. For instance, in the provided example (Fig 1), ReliefF fails to identify the significance of
SNPs 1–3 when run using the complete 50-SNP data, but places at least two of SNPs 1, 2 or 3 in
the top third of selected features when restricted to SNPs 1–12.
While PoDA has many benefits, it should be noted that when epistasis drives a phenotype with
no differences in the minor allele frequencies for the epistatically-interacting genes (as opposed to
a slight yet consistent one shown in the example), PoDA as computed via Eqs. 1,2 will miss the
pathway. Geometrically, such a situation would mean that the case and control groups have the
same centroids while having a different distribution of samples about those centroids. A famous
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example of this is provided through the non-linearly separable XOR (exclusive or): consider two
epistatic loci (X,Y ) such that all controls have genotypes in the set {(0, 0), (1, 1)} and all cases have
genotypes in the set {(0, 1), (1, 0)} (i.e., that a genotype of 1 at either locus can be compensated by
a genotype of 1 at the other, but having just one alone—1 at exclusively X or Y—is deleterious).
If the loci X and Y each have the same MAF in cases and controls, it is plain to see that the
centroids will be in the same location for both groups, and Eq. 1 will yield zero for both cases and
controls. If instead of using Eq. 1, we compute pairwise sample-sample distances, we can circumvent
this limitation and find such epistatic situations (it is this pairwise approach that permits Relief-
F to also uncover nonlinearly interacting SNPs). While we provide the facility for this in the
PoDA package, the cost of carrying out the pairwise computation is a considerable increase in
computational complexity.
A number of potential avenues exist to extend the application of PoDA further. One possible
application is in improving the reproducibility of GWAS results. We note that several of the
pathways identified in the breast cancer GWAS data were also implicated in the liver cancer data,
which suggests that there may be common features which distinguish individuals to cancer generally.
Because different GWA studies—even those of the same phenotypes—often yield different results at
the SNP level, it may be possible to find common alterations at the pathway level across disparate
GWAS using PoDA.
Extending PoDA further, the DSP scores obtained for each pathway may be examined for over-
representation of extreme values in pathways that comprise a particular biological subsystem—one
may think of this as a “pathway-set” enrichment analysis (which would be conducted using the a
running-sum statistic analogous GSEA [17]), and could use it to answer whether (e.g.) immune-
related pathways are hit in liver cancer more often than expected by chance. Alternatively, boost-
ing [56, 57] could be used to find sets of pathways which are more predictive of case status than
individual pathways. Either of these approaches would yield a richer, systems-wide view of the con-
nection between genotype and phenotype. Finally, because PID contains topological information
regarding pathway connectivity, one may consider sub-networks of pathways, permitting one to find
potential chemopreventive and therapeutic targets. Alternatively, Relief-F can be used, as men-
tioned above, in a pathway–specific manner to yield the subset of SNPs that drive the distinction
of cases and controls in high-DSP pathways.
PoDA provides an advantage over existing GWAS analysis methods. Because it does not rely on
the significance of individual markers, it has the power to aid in identifying the genomic causes of
complex diseases that would not be detected in single-gene tests or enrichment analyses. The size
of the SNP set is not limited in PoDA, and since PoDA leverages known biological relationships to
find multi-SNP effects, the results are readily interpretable. PoDA may thus be used to augment
existing analysis techniques and provide a richer, systems-level understanding of genomics.
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Availability
An R package to carry out PoDA is available upon request from the authors (to be deposited in
the Bioconductor in the near future).
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Figure 1: PoDA applied to simulated data. Alleles at 50 loci for 250 cases and 250 controls were
simulated such that each SNP was in HWE and not associated with case status, but homozygous
minor (red) at both loci 1 and 2 or 1 and 3 yielded a three-fold relative risk (a). A 12-SNP pathway
comprising SNPs 1–12 shows differential S distributions (b); a random 12-SNP pathway does not
(c). Boxplots are overlayed on the scatterplots of S for clarity.
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Figure 2: PoDA applied to four highly-significant SNPs. Shown is the distribution of S values in
CGEMS cases (red) and controls (black) for a SNP-set comprised of four highly-significant SNPs
located in the FGFR2 gene [4]. As expected, there is a substantial difference in case and control S
values, with the cases having higher S (i.e., closer to other cases) than controls. The discreteness of
the distributions are due to the fact that with four SNPs, a finite number of S values are possible.
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Figure 3: Four significant pathways in breast cancer data. Scatter plots of SY,P for each pathway
are overlayed with boxplots are given in the left panel; higher values of S indicate that the sample
is closer to other cases than it is to other controls. Distributions of S for cases (red) and controls
(black) are given to the right. A significant shift toward higher S values is seen in the cases. Odds
ratios and FDR-adjusted OR p values are given.
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Figure 4: Four significant pathways in liver cancer data. Scatter plots of SY,P for each pathway
are overlayed with boxplots are given in the left panel; higher values of S indicate that the sample
is closer to other cases than it is to other controls. Distributions of S for cases (red) and controls
(black) are given to the right. A significant shift toward higher S values is seen in the cases. Odds
ratios and FDR-adjusted OR p values are given.
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Figure 5: Union of top three pathways. SNPs from the top three pathways are combined to
compute S for the breast cancer data (a) and the liver cancer data (b). Distributions of S for cases
(red) and controls (black) are given to the right. A significant shift toward higher S values is seen
in the cases.
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Procedure for Pathways of Distinction Analysis
1. For a each pathway P , select all associated genes from pathway database such as PID [32];
2. For each gene on the pathway, select associated SNPs (e.g., using dbSNP) and choose the one
with the strongest association with case status, determined using Fisher’s exact test;
3. For each sample Y in the GWAS, select the controls F and cases G which do not include it,
compute MAFs fi and gi for the SNPs i selected in step 2, and compute SY,P for each sample Y ;
4. Compare the distribution of SY,P obtained in step 2 for cases to that of controls by computing
the Wilcoxon statistic WP based on the SY,P for that pathway;
5. Repeat steps 2–5 using permuted case/control labels, and normalize WP by the distribution
of W ∗P obtained with permuted labels, yielding the distinction score DSP ;
6. Compare the distinction score DSP obtained in step 5 to that obtained for random sets of lP genes,
where lP is the number of genes in the pathway of interest.
Table 1: Procedure for Pathways of Distinction Analysis
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Pathway Source Length DSP p(DSP ) O.R. q(O.R.)
Purine metabolism Kegg 136 1.86 6.36e-03 1.59 4.15e-21
Calcium signaling pathway Kegg 100 1.38 1.82e-03 1.55 6.99e-20
Melanogenesis Kegg 84 2.36 4.55e-03 1.53 1.47e-18
Gap junction Kegg 80 1.54 5.45e-03 1.49 1.49e-16
ErbB signaling pathway Kegg 81 1.36 1.45e-02 1.46 4.68e-15
Long-term potentiation Kegg 60 1.71 9.09e-04 1.45 4.34e-15
GnRH signaling pathway Kegg 79 1.36 1.18e-02 1.44 1.32e-14
TCR signaling in naive CD4+ T cells NCI-Nature 60 2.11 5.45e-03 1.42 7.80e-13
Prostate cancer Kegg 75 1.45 4.09e-02 1.38 4.37e-11
PKC-catalyzed phosphorylation . . . myosin phosphatase BioCarta 20 1.97 <1e-04 1.30 5.82e-09
CCR3 signaling in eosinophils BioCarta 21 1.59 1.09e-02 1.29 8.86e-08
Biosynthesis of unsaturated fatty acids Kegg 18 1.69 2.45e-02 1.26 1.38e-06
Attenuation of GPCR signaling BioCarta 11 1.75 1.09e-02 1.25 2.41e-06
Stathmin and breast cancer resistance to antimicrotubule agents BioCarta 18 1.84 4.82e-02 1.24 4.96e-06
Visual signal transduction: Cones NCI-Nature 20 1.56 4.73e-02 1.24 2.24e-06
Dentatorubropallidoluysian atrophy (DRPLA) Kegg 11 1.84 2.73e-03 1.24 2.24e-06
Intrinsic prothrombin activation pathway BioCarta 22 1.35 3.18e-02 1.23 4.61e-06
Eicosanoid metabolism BioCarta 19 1.69 1.91e-02 1.23 3.44e-06
Effects of botulinum toxin NCI-Nature 7 1.44 2.27e-02 1.20 3.50e-05
Activation of PKC through G-protein coupled receptors BioCarta 10 1.50 9.09e-03 1.20 8.42e-06
Streptomycin biosynthesis Kegg 9 1.36 3.55e-02 1.17 1.89e-04
PECAM1 interactions Reactome 6 2.70 5.45e-03 1.17 7.28e-05
HDL-mediated lipid transport Reactome 8 1.47 2.00e-02 1.14 1.59e-03
Granzyme A mediated apoptosis pathway BioCarta 8 1.97 1.73e-02 1.12 6.60e-04
Table 2: PID pathways with significant DSP in the CGEMS breast cancer GWAS. (Pathways
with over 60% SNPs covered by another pathway have been removed; for the complete list, see
Supplemental Table S-1). Pathway-length based resampled p-values, denoted p(DSP ), are given
for significant pathways, along with the odds ratios and associated FDRs for a logistic regression
model.
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Pathway Source Length DSP p(DSP ) O.R. q(O.R.)
Cell adhesion molecules (CAMs) Kegg 86 1.57 9.09e-03 1.66 3.56e-13
ErbB signaling pathway Kegg 76 1.45 3.45e-02 1.61 2.59e-10
Signaling events mediated by Stem cell factor receptor (c-Kit) NCI-Nature 40 2.35 5.45e-03 1.58 7.31e-10
Neurotrophic factor-mediated Trk receptor signaling NCI-Nature 50 1.60 2.36e-02 1.55 2.49e-08
Lissencephaly gene (LIS1) in neuronal migration and development NCI-Nature 21 2.02 7.27e-03 1.52 1.44e-07
Angiopoietin receptor Tie2-mediated signaling NCI-Nature 40 2.36 1.36e-02 1.51 5.77e-08
Reelin signaling pathway NCI-Nature 28 1.62 5.45e-03 1.46 7.35e-08
Syndecan-4-mediated signaling events NCI-Nature 27 1.74 1.64e-02 1.46 1.19e-06
Galactose metabolism Kegg 19 1.65 2.27e-02 1.44 5.01e-06
Vibrio cholerae infection Kegg 35 1.84 2.64e-02 1.43 6.67e-07
Paxillin-independent events mediated by a4b1 and a4b7 NCI-Nature 19 2.14 1.00e-02 1.40 6.67e-07
Antigen processing and presentation Kegg 34 3.26 1.36e-02 1.40 3.71e-08
Corticosteroids and Cardioprotection BioCarta 21 1.98 3.55e-02 1.39 1.24e-05
Lissencephaly gene (Lis1) in neuronal migration and development BioCarta 15 1.60 1.36e-02 1.37 2.52e-05
IL12 signaling mediated by STAT4 NCI-Nature 25 1.93 4.55e-02 1.37 1.58e-05
Biosynthesis of unsaturated fatty acids Kegg 13 1.76 1.64e-02 1.36 6.44e-05
Growth hormone signaling pathway BioCarta 18 1.75 3.18e-02 1.36 7.46e-05
Canonical Wnt signaling pathway NCI-Nature 28 1.92 4.73e-02 1.35 9.36e-06
NO2-dependent IL-12 pathway in NK cells BioCarta 8 1.82 2.73e-03 1.32 5.83e-05
Signaling events mediated by HDAC Class III NCI-Nature 19 2.12 3.91e-02 1.32 4.19e-05
Removal of aminoterminal propeptides from γ-carboxylated proteins Reactome 7 3.12 5.45e-03 1.29 8.46e-05
Aminophosphonate metabolism Kegg 13 1.91 3.36e-02 1.26 8.17e-04
Antigen processing and presentation BioCarta 6 2.61 1.82e-03 1.22 3.36e-05
Classical complement pathway BioCarta 12 2.27 1.55e-02 1.19 1.67e-04
Chylomicron-mediated lipid transport Reactome 7 1.94 3.27e-02 1.16 1.49e-02
Table 3: PID pathways with significant DSP in the liver cancer GWAS. (Pathways with over
60% SNPs covered by another pathway have been removed; for the complete list, see Supplemental
Table S-2). Pathway-length based resampled p-values, denoted p(DSP ), are given for significant
pathways, along with the odds ratios and associated FDRs for a logistic regression model.
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Pathway Length p(DSP ) O.R. q(O.R.)
Top-2 318 <1e-04 2.02 1.63e-46
Top-3 397 1.00e-04 2.19 2.07e-54
Top-4 474 <1e-04 2.33 3.65e-62
Top-5 522 <1e-04 2.45 6.83e-66
Top-6 544 <1e-04 2.44 8.51e-66
Top-7 558 2.00e-04 2.47 1.22e-67
Top-8 626 <1e-04 2.59 1.01e-73
Top-9 658 <1e-04 2.64 9.84e-75
Top-10 700 <1e-04 2.77 9.72e-79
Top-11 710 <1e-04 2.80 1.42e-79
Top-12 723 <1e-04 2.82 2.06e-80
Top-13 739 <1e-04 2.89 3.31e-82
Top-14 744 <1e-04 2.93 2.86e-83
Top-15 770 <1e-04 2.96 6.41e-85
Top-16 774 <1e-04 2.97 5.10e-85
Top-17 791 <1e-04 2.95 2.43e-85
Top-18 800 <1e-04 3.06 1.15e-87
Top-19 814 <1e-04 3.14 1.19e-89
Top-20 832 <1e-04 3.26 4.51e-92
Top-21 837 <1e-04 3.28 2.92e-92
Top-22 839 <1e-04 3.29 2.41e-92
Top-23 845 <1e-04 3.34 1.45e-93
Top-24 854 <1e-04 3.38 4.62e-95
Table 4: PoDA results for sucessive unions of significant pathways in the CGEMS breast cancer
data. Pathway-length based resampled p values, denotedp(DSP ), are given along with the odds
ratios and associated FDRs for a logistic regression model.
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Pathway Length p(DSP ) O.R. q(O.R.)
Top-2 321 5.38e-02 2.37 1.20e-27
Top-3 402 2.80e-03 2.63 1.40e-34
Top-4 474 1.10e-03 2.86 6.50e-38
Top-5 539 9.00e-04 3.22 4.03e-42
Top-6 560 1.00e-04 3.39 1.19e-43
Top-7 580 <1e-04 3.50 1.39e-44
Top-8 589 6.00e-04 3.50 1.35e-44
Top-9 603 4.00e-04 3.52 1.23e-44
Top-10 624 <1e-04 3.60 1.33e-45
Top-11 640 <1e-04 3.73 3.69e-47
Top-12 646 <1e-04 3.78 1.68e-47
Top-13 667 <1e-04 3.81 9.29e-48
Top-14 709 3.00e-04 3.88 1.90e-48
Top-15 751 <1e-04 4.09 2.11e-49
Top-16 761 <1e-04 4.09 1.76e-49
Top-17 797 <1e-04 4.45 1.29e-50
Top-18 805 <1e-04 4.46 5.24e-51
Top-19 823 <1e-04 4.56 2.20e-51
Top-20 838 <1e-04 4.56 1.73e-51
Table 5: PoDA results for sucessive unions of significant pathways in the liver cancer data.
Pathway-length based resampled p values, denoted p(DSP ), are given along with the odds ratios
and associated FDRs for a logistic regression model.
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Pathway Source Length DSP p(DSP ) O.R. q(O.R.)
Purine metabolism Kegg 136 1.86 6.36e-03 1.59 4.15e-21
Calcium signaling pathway Kegg 100 1.38 1.82e-03 1.55 6.99e-20
Melanogenesis Kegg 84 2.36 4.55e-03 1.53 1.47e-18
Gap junction Kegg 80 1.54 5.45e-03 1.49 1.49e-16
ErbB signaling pathway Kegg 81 1.36 1.45e-02 1.46 4.68e-15
Long-term potentiation Kegg 60 1.71 9.09e-04 1.45 4.34e-15
GnRH signaling pathway Kegg 79 1.36 1.18e-02 1.44 1.32e-14
TCR signaling in naive CD4+ T cells NCI-Nature 60 2.11 5.45e-03 1.42 7.80e-13
TCR signaling in naive CD8+ T cells NCI-Nature 48 2.03 7.27e-03 1.38 1.11e-11
Prostate cancer Kegg 75 1.45 4.09e-02 1.38 4.37e-11
PKC-catalyzed phosphorylation . . . myosin phosphatase BioCarta 20 1.97 <1e-04 1.30 5.82e-09
CCR3 signaling in eosinophils BioCarta 21 1.59 1.09e-02 1.29 8.86e-08
Biosynthesis of unsaturated fatty acids Kegg 18 1.69 2.45e-02 1.26 1.38e-06
Attenuation of GPCR signaling BioCarta 11 1.75 1.09e-02 1.25 2.41e-06
Stathmin and breast cancer resistance to antimicrotubule agents BioCarta 18 1.84 4.82e-02 1.24 4.96e-06
Visual signal transduction: Cones NCI-Nature 20 1.56 4.73e-02 1.24 2.24e-06
Dentatorubropallidoluysian atrophy (DRPLA) Kegg 11 1.84 2.73e-03 1.24 2.24e-06
Intrinsic prothrombin activation pathway BioCarta 22 1.35 3.18e-02 1.23 4.61e-06
Eicosanoid metabolism BioCarta 19 1.69 1.91e-02 1.23 3.44e-06
Effects of botulinum toxin NCI-Nature 7 1.44 2.27e-02 1.20 3.50e-05
Activation of PKC through G-protein coupled receptors BioCarta 10 1.50 9.09e-03 1.20 8.42e-06
Ca-calmodulin-dependent protein kinase activation BioCarta 8 1.70 1.00e-02 1.19 5.67e-05
Streptomycin biosynthesis Kegg 9 1.36 3.55e-02 1.17 1.89e-04
PECAM1 interactions Reactome 6 2.70 5.45e-03 1.17 7.28e-05
HDL-mediated lipid transport Reactome 8 1.47 2.00e-02 1.14 1.59e-03
Granzyme A mediated apoptosis pathway BioCarta 8 1.97 1.73e-02 1.12 6.60e-04
Table S-1: Full list PID pathways with significantDSP in the breast cancer GWAS, including highly
“overlapping” pathways. Pathway-length based resampled p-values, denoted p(DSP ), are given for
significant pathways, along with the odds ratios and associated FDRs for a logistic regression model.
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Pathway Source Length DSP p(DSP ) O.R. q(O.R.)
Cell adhesion molecules (CAMs) Kegg 86 1.57 9.09e-03 1.66 3.56e-13
ErbB signaling pathway Kegg 76 1.45 3.45e-02 1.61 2.59e-10
Signaling events mediated by Stem cell factor receptor (c-Kit) NCI-Nature 40 2.35 5.45e-03 1.58 7.31e-10
Neurotrophic factor-mediated Trk receptor signaling NCI-Nature 50 1.60 2.36e-02 1.55 2.49e-08
Lissencephaly gene (LIS1) in neuronal migration and development NCI-Nature 21 2.02 7.27e-03 1.52 1.44e-07
Angiopoietin receptor Tie2-mediated signaling NCI-Nature 40 2.36 1.36e-02 1.51 5.77e-08
Reelin signaling pathway NCI-Nature 28 1.62 5.45e-03 1.46 7.35e-08
Syndecan-4-mediated signaling events NCI-Nature 27 1.74 1.64e-02 1.46 1.19e-06
Galactose metabolism Kegg 19 1.65 2.27e-02 1.44 5.01e-06
TPO signaling pathway BioCarta 17 2.61 6.36e-03 1.44 3.80e-06
Vibrio cholerae infection Kegg 35 1.84 2.64e-02 1.43 6.67e-07
Paxillin-independent events mediated by a4b1 and a4b7 NCI-Nature 19 2.14 1.00e-02 1.40 6.67e-07
Antigen processing and presentation Kegg 34 3.26 1.36e-02 1.40 3.71e-08
Corticosteroids and cardioprotection BioCarta 21 1.98 3.55e-02 1.39 1.24e-05
Lissencephaly gene (Lis1) in neuronal migration and development BioCarta 15 1.60 1.36e-02 1.37 2.52e-05
IL12 signaling mediated by STAT4 NCI-Nature 25 1.93 4.55e-02 1.37 1.58e-05
Biosynthesis of unsaturated fatty acids Kegg 13 1.76 1.64e-02 1.36 6.44e-05
Growth hormone signaling pathway BioCarta 18 1.75 3.18e-02 1.36 7.46e-05
Canonical Wnt signaling pathway NCI-Nature 28 1.92 4.73e-02 1.35 9.36e-06
NO2-dependent IL-12 pathway in nk cells BioCarta 8 1.82 2.73e-03 1.32 5.83e-05
Signaling events mediated by HDAC Class III NCI-Nature 19 2.12 3.91e-02 1.32 4.19e-05
Removal of aminoterminal propeptides from gamma-carboxylated proteins Reactome 7 3.12 5.45e-03 1.29 8.46e-05
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins Reactome 6 3.25 1.82e-03 1.28 6.64e-05
Transport of γ-carboxylated protein precursors . . . Reactome 6 3.25 1.82e-03 1.28 6.64e-05
Paxillin-dependent events mediated by a4b1 NCI-Nature 17 1.84 2.00e-02 1.28 3.41e-05
Gamma-carboxylation of protein precursors Reactome 7 2.86 3.64e-03 1.28 1.38e-04
Aminophosphonate metabolism Kegg 13 1.91 3.36e-02 1.26 8.17e-04
Antigen processing and presentation BioCarta 6 2.61 1.82e-03 1.22 3.36e-05
Lectin induced complement pathway BioCarta 11 1.91 2.18e-02 1.20 1.55e-04
Classical complement pathway BioCarta 12 2.27 1.55e-02 1.19 1.67e-04
Chylomicron-mediated lipid transport Reactome 7 1.94 3.27e-02 1.16 1.49e-02
Table S-2: Full list PID pathways with significant DSP in the liver cancer GWAS, including highly
“overlapping” pathways. Pathway-length based resampled p-values, denoted p(DSP ), are given for
significant pathways, along with the odds ratios and associated FDRs for a logistic regression model.
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